Notably, treatment costs for heart failure are also lower in the Czech Republic as sodium-glucose cotransporter-2 inhibitors (SGLT2is) were excluded from the original analysis as they were not reimbursed by the public payer at the point of survey conduct. This evidence concerns the gene SLC5A2 and heart failure.